Predict your next investment

Venture Capital
health-ventures.com

See what CB Insights has to offer

Investments

47

Portfolio Exits

16

Funds

2

About CB Health Ventures

CB Health Ventures was the venture capital arm of Cain Brothers & Company and is focused on emerging growth and early stage companies. CB Health Ventures is no longer making investments. When investing, the firm sought to invest in the healthcare sector with a focus on healthcare services, medical information technology, biotechnology, and genomics. The firm typically invested between $500,000 and $7 million. CB Health Ventures was headquartered in Boston, Massachusetts with an additional office in New York, New York.

CB Health Ventures Headquarter Location

800 Boylston Street

Boston, Massachusetts, 02199,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest CB Health Ventures News

PathoGenetiX Adds $4M in VC

Aug 1, 2011

PathoGenetiX Adds $4M in VC August 1, 2011 Woburn, Mass.-based PathoGenetiX Inc., a developer of genome sequence scanning technology, has raised $4 million in a first close of its Series B financing. Excel Venture Management led the round, which also included investments from CB Health Ventures and HealthCare Ventures. The company has sealed commitments for $9.5 million in total Series B financing. PRESS RELEASE PathoGenetiX Inc., today announced that the Company has received $4.0 million in the first closing of its Series B financing. The Company has received $9.5 million in commitments from investors for the Series B. The funds will be used to complete development of PathoGenetiX’s first commercial systems for identifying pathogens in complex biological samples using its proprietary Genome Sequence Scanning technology. Excel Venture Management led the financing, which also included investments from CB Health Ventures, HealthCare Ventures, and other investors who participated in the Company’s Series A financing in the fall 2010. The Company’s Genome Sequence Scanning technology can simultaneously identify thousands of bacterial strains in a single test in three hours. The technology’s rapid time to answer and ability to identify specific strains at low cost holds great potential for a wide range of applications, including: accelerating infectious disease diagnosis and improving the selection of antibiotic therapy; streamlining clinical trials; reducing the time for detection and source tracking of life-threatening food-borne pathogens from weeks to hours; enhancing biosecurity; and advancing research on microbial populations. The clinical need and potential economic benefit from rapid detection and identification of pathogens at the strain level is enormous. Delayed or incorrect diagnosis results in more than 225,000 deaths, including 100,000 from hospital-acquired infections in the U.S. alone each year according to the Centers for Disease Control. Delayed diagnosis costs the U.S. healthcare system an estimated $10 billion annually in extended hospital stays and medication costs. Food-borne contamination exacts a significant toll in illness and economic loss, despite more than $1 billion spent per year on pathogen contamination testing. Food-borne illness affects an estimated 75 million people in the U.S. annually, resulting in 325,000 hospitalizations and 5,000 deaths. “Genome Sequence Scanning is a revolutionary platform for providing an approach to pathogen detection and management that can improve outcomes for patients, improve food safety, and reduce costs,” said Dr. Enrico Petrillo, MD, Managing Director at Excel Venture Management. “Rapid detection and identification of infectious pathogens at the strain level can provide clinicians and other users with more information, sooner, for making critical, time sensitive decisions.” Genome Sequence Scanning technology was initially developed with more than $50 million in support from the United States Departments of Defense and Homeland Security under their advanced biosensor programs. The technology extracts genomic barcodes from microbial DNA as it flows through a microfluidic chip at 150 million base pairs per second. Complex clinical specimens can be scanned to identify thousands of pathogenic strains days faster and at lower cost than current diagnostic techniques. “The financing reflects the outstanding progress we have made to demonstrate Genome Sequence Scanning’s unique capabilities on a comprehensive range of samples including clinical, environmental, and food products, using commercial prototypes of the instrumentation systems,” said John J. Canepa, PathoGenetiX CEO. “The funding will allow us to complete development of our first commercial systems, enter the rapidly growing research market for microbiome analysis, and advance the development of applications for food and product safety and clinical diagnostics.” About Excel Venture Management Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond. The Excel investment portfolio is balanced across healthcare IT and services, diagnostics, and medical devices, plus life science platforms that address adjacent markets including energy, chemicals, defense and agriculture. About PathoGenetiX PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company’s approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with initial commercial introduction into the research market planned for 2012. © 2015 Buyouts Insider / Argosy Group LLC

CB Health Ventures Investments

47 Investments

CB Health Ventures has made 47 investments. Their latest investment was in PathoGenetix as part of their Series B - II on November 11, 2011.

CBI Logo

CB Health Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/1/2011

Series B - II

PathoGenetix

$7.5M

No

1

7/18/2011

Series B

PathoGenetix

$4M

No

2

5/3/2011

Series E

IntraPace

$15.4M

No

11/16/2010

Series A

Subscribe to see more

$99M

Subscribe to see more

0

9/18/2009

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

0

Date

11/1/2011

7/18/2011

5/3/2011

11/16/2010

9/18/2009

Round

Series B - II

Series B

Series E

Series A

Unattributed VC

Company

PathoGenetix

PathoGenetix

IntraPace

Subscribe to see more

Subscribe to see more

Amount

$7.5M

$4M

$15.4M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

0

0

CB Health Ventures Portfolio Exits

16 Portfolio Exits

CB Health Ventures has 16 portfolio exits. Their latest portfolio exit was TransMedics on May 02, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/2/2019

IPO

$99M

Public

2

9/9/2015

Acquired

$99M

1

2/13/2015

Asset Sale

$99M

1

7/22/2013

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/4/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/2/2019

9/9/2015

2/13/2015

7/22/2013

4/4/2011

Exit

IPO

Acquired

Asset Sale

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

CB Health Ventures Fund History

2 Fund Histories

CB Health Ventures has 2 funds, including CB Healthcare II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2001

CB Healthcare II LP

Multi-Stage Venture Capital

Closed

$73M

1

12/31/1998

CB Healthcare I LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2001

12/31/1998

Fund

CB Healthcare II LP

CB Healthcare I LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$73M

$99M

Sources

1

10

CB Health Ventures Team

1 Team Member

CB Health Ventures has 1 team member, including current Founder, Enrico Petrillo.

Name

Work History

Title

Status

Enrico Petrillo

Excel Venture Management, and Fletcher Spaght

Founder

Current

Name

Enrico Petrillo

Work History

Excel Venture Management, and Fletcher Spaght

Title

Founder

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.